Juvenescence is a biopharmaceutical company that has raised USD $165 million since 2017 to build a pipeline of therapeutic assets to target aging, regeneration and the diseases of aging.
As people age, complex changes occur at the genomic, cellular and tissue level, from the accumulation of DNA damage to mitochondrial dysfunction and altered intercellular communication.
These changes, among others, cause the diseases of aging that affect the elderly, and the chronic illnesses that are the biggest burden on the healthcare system.
Aging is the largest health problem facing the world today; two-thirds of all deaths worldwide are as a result of the aging process, with many years of degeneration reducing quality of life before death.
Our work is based on novel scientific understanding of the underlying biological causes of aging, to create evidence-based therapeutics that can treat diseases of aging.
Juvenescence creates and partners with new companies with longevity-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures with the foremost longevity scientists and leading research institutions.
Juvenescence aims to create a paradigm shift in addressing and treating disease.
Our goal is to extend both lifespan and healthspan, by developing therapeutics that slow aging and promote juvenescence (”the state or period of being young”).
Ultimately, Juvenescence aims to get therapeutics to patients, and eradicate life-shattering diseases that cause people to suffer until death.
Juvenescence leverages its world-class team to translate rigorous science into disease-modifying therapeutics.
Our growing pipeline of therapeutic assets targets fundamental aging, regeneration, and the diseases of aging. Click below to the full pipeline to learn more about each company.
Extension of NetraMark’s NetraPharma Collaboration with Juvenescence
NetraMark Corp., a next generation AI + health data technology company and Juvenescence Limited, a life sciences company utilizing expert drug developers and artificial intelligence experts to create therapeutics and technologies to treat diseases of aging and to increase human longevity, are pleased to announce the extension of their…Read more
AgeX Therapeutics Issues Year-End Letter to Shareholders
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, issued a letter to shareholders from Michael D. West, PhD, founder and CEO, and Gregory Bailey, MD, Chairman, reflecting on progress made in AgeX’s first year as a public company,…Read more
Please complete the form below to get in touch with the Juvenescence team.